Ministry of Health to evaluate report on human trial research data of domestic vaccine Nanocovax
The Ministry of Health has asked Nanogen Pharmaceutical Biotechnology Joint Stock Company – the manufacturer of the Nanocovax vaccine – to submit report on phase 2 and phase 3 clinical trial research data to the ministry prior to August 15.
Latest
 |
| Nanocovax, currently in phase 3 of human trials, is the most promising candidate among four domestic vaccines being developed by Viet Nam. (Source: VGP) |
Based on the report, the National Ethnic Council and the Council for Consultancy and Licensing of Medical Devices under the Ministry of Health will consider approval for emergency use of Nanocovax in Viet Nam.
Nanocovax, currently in phase 3 of human trials, is the most promising candidate among four domestic vaccines being developed by Viet Nam. The others are being developed by the Institute of Vaccines and Medical Biologicals, the Vaccine and Biological Production Company No. 1, and the Center for Research and Production of Vaccines and Biologicals.
According to Nanogen, Nanocovax’s immunogenicity reached 99.4 per cent, equally to those of other COVID-19 vaccines licensed in the world.
Viet Nam has approved six Covid-19 vaccines for emergency use, namely Janssen, Moderna, Sputnik V, Pfizer, Sinopharm, and AstraZeneca.
The Government of Viet Nam is making every effort to secure at least 150 million vaccine doses this year to cover 70% of the population.
(Source: VGP)
